KYORIN Holdings Inc (4569) - Financial and Strategic SWOT Analysis Review

  • ID: 4418440
  • SWOT Analysis
  • 39 pages
  • GlobalData
1 of 5

FEATURED COMPANIES

  • Astellas Pharma Inc
  • Nippon Shinyaku Co Ltd
  • Teijin Ltd
  • MORE
KYORIN Holdings Inc (4569) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:
  • Business description - A detailed description of the company’s operations and business divisions.
  • Corporate strategy - Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history - Progression of key events associated with the company.
  • Major products and services - A list of major products, services and brands of the company.
  • Key competitors - A list of key competitors to the company.
  • Key employees - A list of the key executives of the company.
  • Executive biographies - A brief summary of the executives’ employment history.
  • Key operational heads - A list of personnel heading key departments/functions.
  • Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
  • Key manufacturing facilities - A list of key manufacturing facilities of the company.
  • Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights

KYORIN Holdings Inc (KYORIN), formerly known as KYORIN Co.,Ltd., is a holding company. Its business activities include controlling, administering and supporting companies, which conduct various businesses by holding the shares of those companies. The company through its subsidiaries carries out the discovery, manufacturing and sale of pharmaceuticals including new ethical drugs, generic drugs and the over-the-counter (OTC) drugs. It also provides consumer healthcare products including beauty and good health products. KYORIN provides product under Kipres, Mucodyne, Pentasa, Uritos, Ketas, Flutiform, Milton, Rubysta and other brands. KYORIN is headquartered in Chiyoda-Ku, Tokyo, Japan.

KYORIN Holdings Inc Key Recent Developments

Jun 06, 2017: PeptiDream Announces First Milestone from Macrocyclic Peptide Drug Discovery Alliance with Kyorin
Feb 22, 2017: Kyorin: Change of Representative Director and President at ActivX Biosciences
Feb 22, 2017: Kyorin Holdings: Establishment of a Representative Office in the Republic of Indonesia

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
  • The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
  • The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
  • Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
  • Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
  • Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Astellas Pharma Inc
  • Nippon Shinyaku Co Ltd
  • Teijin Ltd
  • MORE
Section 1 - About the Company
  • KYORIN Holdings Inc - Key Facts
  • KYORIN Holdings Inc - Key Employees
  • KYORIN Holdings Inc - Key Employee Biographies
  • KYORIN Holdings Inc - Key Operational Employees
  • KYORIN Holdings Inc - Major Products and Services
  • KYORIN Holdings Inc - History
  • KYORIN Holdings Inc - Company Statement
  • KYORIN Holdings Inc - Locations And Subsidiaries
  • Head Office
  • Other Locations & Subsidiaries
Section 2 - Company Analysis
  • KYORIN Holdings Inc - Business Description
  • KYORIN Holdings Inc - Corporate Strategy
  • KYORIN Holdings Inc - SWOT Analysis
  • SWOT Analysis - Overview
  • KYORIN Holdings Inc - Strengths
  • KYORIN Holdings Inc - Weaknesses
  • KYORIN Holdings Inc - Opportunities
  • KYORIN Holdings Inc - Threats
  • KYORIN Holdings Inc - Key Competitors
Section 3 - Company Financial Ratios
  • Financial Ratios - Capital Market Ratios
  • Financial Ratios - Annual Ratios
  • Performance Chart
  • Financial Performance
  • Financial Ratios - Interim Ratios
  • Financial Ratios - Ratio Charts
Section 4 - Company’s Lifesciences Financial Deals and Alliances
  • KYORIN Holdings Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017
  • KYORIN Holdings Inc, Pharmaceuticals & Healthcare, Deals By Type, 2011 to YTD 2017
  • KYORIN Holdings Inc, Recent Deals Summary
Section 5 - Company’s Recent Developments
  • Jun 06, 2017: PeptiDream Announces First Milestone from Macrocyclic Peptide Drug Discovery Alliance with Kyorin
  • Feb 22, 2017: Kyorin: Change of Representative Director and President at ActivX Biosciences
  • Feb 22, 2017: Kyorin Holdings: Establishment of a Representative Office in the Republic of Indonesia
Section 6 - Appendix
  • Methodology
  • Ratio Definitions
  • About
  • Contact
  • Disclaimer
List of Tables
  • KYORIN Holdings Inc, Key Facts
  • KYORIN Holdings Inc, Key Employees
  • KYORIN Holdings Inc, Key Employee Biographies
  • KYORIN Holdings Inc, Key Operational Employees
  • KYORIN Holdings Inc, Major Products and Services
  • KYORIN Holdings Inc, History
  • KYORIN Holdings Inc, Subsidiaries
  • KYORIN Holdings Inc, Key Competitors
  • KYORIN Holdings Inc, Ratios based on current share price
  • KYORIN Holdings Inc, Annual Ratios
  • KYORIN Holdings Inc, Annual Ratios
  • KYORIN Holdings Inc, Annual Ratios
  • KYORIN Holdings Inc, Interim Ratios
  • KYORIN Holdings Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017
  • KYORIN Holdings Inc, Pharmaceuticals & Healthcare, Deals By Type, 2011 to YTD 2017
  • KYORIN Holdings Inc, Recent Deals Summary
  • Currency Codes
  • Capital Market Ratios
  • Equity Ratios
  • Profitability Ratios
  • Cost Ratios
  • Liquidity Ratios
  • Leverage Ratios
  • Efficiency Ratios
List of Figures
  • KYORIN Holdings Inc, Performance Chart (2013 - 2017)
  • KYORIN Holdings Inc, Ratio Charts
  • KYORIN Holdings Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017
  • KYORIN Holdings Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Torii Pharmaceutical Co Ltd
  • Teijin Ltd
  • Santen Pharmaceutical Co Ltd
  • Nippon Shinyaku Co Ltd
  • Mochida Pharmaceutical Co Ltd
  • Astellas Pharma Inc
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll